Savara initiates rolling submission of a biologics license application (bla) to the u.s. food and drug administration (fda) for molbreevi* for the potential treatment of autoimmune pulmonary alveolar proteinosis (apap)

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a bla to the fda for molbreevi for the potential treatment of apap, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. molbreevi was granted fast track and breakthrough therapy designations in 2019 for the treatment of patients with.
SVRA Ratings Summary
SVRA Quant Ranking